Skip to main content

Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort



We assessed the feasibility of plasma Aβ42/Aβ40 determined using a novel liquid chromatography-mass spectrometry method (LC-MS) as a useful biomarker of PET status in a Korean cohort from the DPUK Study.


A total of 580 participants belonging to six groups, Alzheimer’s disease dementia (ADD, n = 134), amnestic mild cognitive impairment (aMCI, n = 212), old controls (OC, n = 149), young controls (YC, n = 15), subcortical vascular cognitive impairment (SVCI, n = 58), and cerebral amyloid angiopathy (CAA, n = 12), were included in this study. Plasma Aβ40 and Aβ42 were quantitated using a new antibody-free, LC-MS, which drastically reduced the sample preparation time and cost. We performed receiver operating characteristic (ROC) analysis to develop the cutoff of Aβ42/Aβ40 and investigated its performance predicting centiloid-based PET positivity (PET+).


Plasma Aβ42/Aβ40 were lower for PET+ individuals in ADD, aMCI, OC, and SVCI (p < 0.001), but not in CAA (p = 0.133). In the group of YC, OC, aMCI, and ADD groups, plasma Aβ42/Aβ40 predicted PET+ with an area under the ROC curve (AUC) of 0.814 at a cutoff of 0.2576. When adding age, APOE4, and diagnosis, the AUC significantly improved to 0.912.


Plasma Aβ42/Aβ40, as measured by this novel LC-MS method, showed good discriminating performance based on PET positivity.


Alzheimer’s disease (AD) is characterized by amyloid β (Aβ) deposition in the brain. Due to the rapid development of Aβ biomarker testing, earlier diagnosis of AD has become possible. Currently, Aβ positron emission tomography (PET) and cerebrospinal fluid (CSF) are the most validated methods for detection of the fibrillary and soluble forms of Aβ, respectively [1]. However, as these methods have limitations in terms of cost, accessibility, exposure to radiation, and invasiveness, the need for blood biomarkers that are more easily accessible has been increasing. Some studies have attempted to prove the clinical utility of plasma Aβ biomarker by investigating its correspondence with Aβ PET and CSF [2,3,4,5,6,7,8,9,10,11]. Particularly, recent studies that used immunoprecipitation-mass spectrometry (IP-MS) to measure plasma Aβ42/Aβ40 showed promising results with high predictive accuracy for PET positivity [5, 8, 12].

Although the exact physiology underlying the pathological production and clearance of plasma Aβ remains unclear, there is increasing evidence that Aβ in the brain is cleared via transport into the plasma through the blood-brain barrier (BBB) or CSF [13]. In terms of the BBB transport of Aβ, there are several factors that have been known to affect it. Increased age is associated with impaired BBB transport of Aβ [14]. Depending on the genotype, APOE protein is also known to affect Aβ transport by combining differently with Aβ and lipoprotein receptor-related protein [15, 16]. Changes in Aβ fluid biomarkers may occur earlier than Aβ PET in the preclinical phase of the AD continuum [17, 18], as it is known that the dysregulated kinetics of soluble Aβ precedes Aβ deposition in the brain [19]. In fact, previous studies have shown that most discordant cases in preclinical AD were CSF+/PET− [17]. Although it has not been as thoroughly investigated as CSF, it would be reasonable to expect that most discordant cases in preclinical AD might also be plasma+/PET−. However, considering that Aβ kinetics in the plasma Aβ level changes as the disease progresses [5], the association of plasma Aβ and Aβ deposition in the brain might vary depending on the three cognitive stages: normal control, mild cognitive impairment (MCI), and dementia. Thus, we can assume that age, APOE genotype, and the cognitive stage might affect the relationship between the plasma Aβ level and Aβ deposition detected on PET.

Subcortical vascular cognitive impairment (SVCI) is characterized by extensive cerebrovascular diseases (CVD), such as white matter hyperintensities (WMH) and lacunes on MRI. CVD is an important clinical factor that could damage BBB through various mechanisms such as ischemia, oxidative stress, and inflammation. Subsequently, these BBB damages may affect Aβ clearance, which in turn may result in plasma Aβ changes. In fact, previous studies have reported that WMH is associated with plasma Aβ40 or Aβ42 [3, 20]. Thus, patients with SVCI might show a different performance from patients on the AD continuum in their plasma Aβ42/Aβ40, which predicts Aβ PET positivity.

In the present study, we aimed to investigate the predictive accuracy of plasma Aβ42/Aβ40, using a specific liquid chromatography-MS (LC-MS) method in a large-sized cohort which included various cognitive stages and etiologies. First, we performed a 10-fold cross-validation in patients across the AD continuum. We hypothesized that the plasma Aβ42/Aβ40 would successfully predict PET positivity and that the predictive performance would increase if age, APOE genotype, and cognitive stage were included in the model. Then, to investigate whether CVD may affect the predictive performance of plasma Aβ42/Aβ40 for PET positivity, we also validated our model in patients with SVCI.

Materials and methods


This study cohort of 580 participants represents a sample obtained from the memory clinic at Samsung Medical Center between 2017 and 2019. The selection process is shown in Supplementary Figure 1. All participants underwent brain magnetic resonance imaging (MRI) and Aβ PET with either 18F-florbetaben (FBB) or 18F-flutemetamol (FMM) [21]. The study participants were divided into six diagnostic groups: young controls (YC, cognitively unimpaired individuals younger than 45 years), old controls (OC, cognitively unimpaired individuals older than 45 years), amnestic mild cognitive impairment (aMCI), Alzheimer’s disease dementia (ADD), SVCI, and CAA. All participants, except the YCs, underwent detailed neuropsychological tests called the Seoul Neuropsychological Screening Battery (SNSB) [21]. YCs (n = 15) were healthy volunteers without a history of neurological or psychiatric disorders. OCs (n = 149) were defined to have normal cognition on neuropsychological tests (above the −1.0 standard deviation (SD) of age- and education-matched norms in memory and −.1.5 SD in other cognitive domains [22]) without a history of neurological or psychiatric disorders. aMCI (n = 212) was defined using Petersen’s criteria for MCI [23]. Probable ADD (n = 134) [24] was defined using the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s disease and Related Disorders Association criteria [25]. Those with aMCI or ADD had WMH that were either minimal (periventricular WMH < 5 mm and deep WMH < 5 mm) or moderate (between minimal and severe WMH classifications) based on the Fazekas ischemia criteria [26]. SVCI (n = 58, subcortical vascular MCI and subcortical vascular dementia) was defined when patients met all three of the following criteria: (1) subjective cognitive complaints by the patient or caregiver; (2) objective cognitive impairment below the 16th percentile in any domain including language, visuospatial, memory, or frontal function on neuropsychological tests; and (3) severe ischemia on brain MRI, defined as periventricular WMH ≥ 10 mm and deep WMH ≥ 25 mm, as modified from the Fazekas ischemia criteria [26]. CAA (n = 12) was defined when the individuals met the modified Boston criteria for probable CAA [27,28,29] regardless of cognitive status.

All participants were assessed through clinical interviews and neurologic examinations, and clinical diagnoses were established by consensus among a multidisciplinary team. Blood tests included complete blood count, blood chemistry tests, vitamin B12/folate measurement, syphilis serology, thyroid function test, and APOE genotyping. Patients were excluded if they had territorial infarctions, cortical stroke, brain tumor, or vascular malformation on MRI. Patients with WMH due to radiation injury, multiple sclerosis, vasculitis, or leukodystrophy were also excluded.

This study was approved by the institutional review board of Samsung Medical Center.

Plasma collection and processing

We obtained 8 mL of blood from each participant and placed into a 0.5 M EDTA-containing tube and mixed it for 5 min. The Green Cross lab picked up the samples that were stocked in the cooler after mixing. Plasma was extracted from the blood sample after a 10-min centrifuge (1300 g) and dispensed into 5 or 10 vials at a volume of 0.3 mL each. All plasma samples were kept frozen at −75 °C until LC-MS analysis. The process complied with the manual for human resource collection and registration of the National Biobank of the Republic of Korea [30]. The median interval between plasma collection and Aβ PET scans was 0.5 days (interquartile range, 0–37.5 days).

Liquid chromatography-mass spectrometry (LC-MS)

The prepared plasma samples were sent to Araclon Biotech (Zaragoza, Spain) and analyzed using LC-MS. Plasma samples were analyzed using a novel antibody-free liquid chromatography-differential mobility spectrometry-triple quadrupole mass spectrometry (HPLC-DMS-MS/MS) method. The analytical platform was composed of a QTRAP 6500+ hybrid linear ion trap-triple quadrupole mass spectrometer fitted with a differential mobility spectrometry interface (SelexION) and coupled to an M3 Micro LC system (Sciex, Framingham, MA, USA). Samples (200 μL each) were analyzed singles. Analytes were extracted directly from plasma, and no immunoprecipitation procedure was performed. Intact Aβ40 and Aβ42 species were analyzed as no enzymatic digestion was performed. The specifics of the method are the subject matter of patent application (EP2020382352) that will be publicly available for inspection within 18 months of its filing date.

Analysis of mass spectrometry data

Calibration curves were prepared in human plasma after spiking 15N-Aβ40 and 15N-Aβ42 at seven concentration levels. Quality control samples were also prepared in human plasma at three concentration levels (low: 3 × LLOQ, mid, and high). The calibration ranges were 50–1000 pg/mL for 15N-Aβ40 and 10–200 pg/mL for 15N-Aβ42. The LLOQ for 15N-Aβ40 was 50 pg/mL (% relative error RE = 0.3% and coefficient of variation CV = 7%). The LLOQ for 15N-Aβ42 was 10 pg/mL (RE = −1.5% and CV = 11%).

Two calibration curves were used in each analytical run, one at the beginning and one at the end of the sequence. Additionally, six quality control samples, uniformly distributed along the sequence, were analyzed in each run.

Deuterated internal standards (2H-Aβ40 and 2H-Aβ42) were spiked in all samples (calibration curves, quality control, and study samples). Response ratios corresponding to endogenous species in the study samples (14N-Aβ40/2H-Aβ40 and 14N-Aβ42/2H-Aβ42) were interpolated in the calibration curves made with 15N analogues. Suitability test samples were analyzed every day at the beginning of the analytical run to evaluate system performance and equal transmission for light (14N) and heavy (15N) species.

Analyst 1.6.3. Software (Sciex) was used for data acquisition, and the MultiQuant 3.0.3. software (Sciex) was used for data processing.

Eight participants (one OC, two with aMCI, four with ADD, and one with SVCI) with Aβ40 values below the lower limit of quantification (<LLQ) were excluded from the analysis.

Brain MRI

All participants underwent standardized T2, 3-dimensional T1 turbo field echo images, 3-dimensional (3D) fluid-attenuated inversion-recovery (FLAIR), and T2×-weighted gradient echo (GRE)-MRIs at Samsung Medical Center using a 3.0T MRI scanner (Philips 3.0T Achieva; Philips Healthcare, Andover, MA, USA) [31]. The following parameters were used for the T2* GRE images: axial slice thickness 5.0 mm, inter-slice thickness 2 mm, repetition time (TR) 669 ms, echo time (TE) 16 ms, flip angle 18°, and matrix size 560 × 560 pixels. We acquired 3D T1 images with the following parameters: sagittal slice thickness 1.0 mm, over contiguous slices with 50% overlap, TR 9.9 ms, TE 4.6 ms, flip angle 8°, and matrix size 240 × 240 pixels, reconstructed to 480 × 480 over a field of view of 240 mm. 3D FLAIR images were obtained with the following parameters: axial slice thickness 2 mm, no gap, TR 11,000 ms, TE 125 ms, flip angle 90°, and matrix size 512 × 512 pixels.

Aβ PET imaging acquisition, analysis, centiloid, and definition of Aβ positivity

All participants underwent either FBB or FMM PET at Samsung Medical Center using a Discovery STe PET/CT scanner (GE Medical Systems, Milwaukee, WI, USA) in 3D scanning mode that examined 47 slices of 3.3-mm thickness spanning the entire brain [32, 33]. CT images were acquired using a 16-slice helical CT (140 KeV, 80 mA; 3.75-mm section width) for attenuation correction. According to the protocols proposed by the ligands’ manufacturers, a 20-min emission PET scan with dynamic mode (consisting of 4 × 5 min frames) was performed 90 min after injection of a mean dose of 311.5 MBq of FBB or 185 MBq of FMM. 3D PET images were reconstructed in a 128 × 128 × 48 matrix with a voxel size of 2 mm × 2 mm × 3.27 mm using the ordered-subsets expectation maximization algorithm (FBB iterations = 4 and subset = 20; FMM iterations = 4 and subset = 20).

PET images were co-registered to individual MRIs normalized to a T1-weighted MNI-152 template using SPM8 through MATLAB2014b (Mathworks, Natick, MA, USA). After standard space registration, the brain was divided into 116 gray matter regions using the Automated Anatomical Labeling atlas [34]. The global standard uptake value ratio (SUVR) was obtained with reference to the whole cerebellum to quantify FBB and FMM retention, from the volume-weighted average SUVR of 28 bilateral cerebral cortical volumes-of-interest (VOIs) [32, 35]. The SUVR cutoff value for Aβ positivity was calculated using the iterative outlier approach [36, 37], which removes cases from cognitively normal participants over 55 years of age until all outliers are excluded. Once all outliers are removed from the dataset, 2.5% is added to the SUVR of the highest remaining case, which results in a cutoff value [36]. As a result, the cortical SUVR cutoff values were 1.1 for FBB and 1.03 for FMM, respectively, when the whole cerebellum was used as a reference region [37, 38].

In our previous study, we directly converted the SUVR values of the FBB or FMM CTX VOI into direct comparison centiloid units (dcCL) using the dcCL conversion equation [39, 40]. One AD patient (with Aβ40 < LLQ) and one CAA patient were excluded due to imaging analysis errors. To obtain the dcCL cutoff value for Aβ positivity, we performed receiver operating characteristic (ROC) analysis using Aβ positivity based on the SUVR cutoff for each PET as the standard of truth. Therefore, the dcCL cutoff value was 25.11 with an area under the curve (AUC) of 0.994, and we defined Aβ positivity using this dcCL cutoff in this study (Supplementary Figure 2).

Statistical analyses

We compared plasma Aβ40, Aβ42, and Aβ42/Aβ40 between Aβ PET-positive and PET-negative participants in each diagnostic group using the Mann-Whitney U test. We investigated the correlation between plasma Aβ42/Aβ40 and dcCL units using Spearman’s correlation analysis. We then performed logistic regression followed by ROC analyses to establish the performance of Aβ42/Aβ40 predicting dcCL-based Aβ PET positivity (unadjusted model) in the AD continuum. The Aβ42/Aβ40 cutoff was defined as the value that gives the maximum Youden index (sensitivity + specificity − 1) from this ROC analysis. We then calculated the positive percent agreement (PPA), which was defined as the proportion of dcCL-based PET-positive participants that are plasma positive, and negative percent agreement (NPA), which was defined as the proportion of dcCL-based PET-negative participants that were plasma negative. We defined plasma Aβ42/Aβ40 as abnormal (plasma+) when it was lower than the cutoff value. Therefore, the concordance rate of Aβ PET and plasma biomarker results was calculated as the number of plasma+/PET+ plus plasma−/PET− cases over the total number of participants in the analysis.

To evaluate whether concordance rate differs according to different Aβ PET positivity cutoffs, we performed a sensitivity analysis using two Aβ dcCL cutoffs: (1) the first cutoff of 24.6 was obtained from the ROC analysis using amyloid positivity based on visual reading (instead of SUVR cutoff) as the standard of truth, and (2) the second cutoff of 20 was arbitrarily selected, given that this is a cutoff for the presence of at least moderate plaque density based on a previous pathology study [41].

We performed ROC analyses using a 10-fold cross-validation in AD continuum including YC, OC, aMCI, and ADD to increase the reliability of the model for predicting dcCL-based Aβ PET positivity with different combinations of variables: age, presence of APOE4 (either heterozygotes or homozygotes), and cognitive stage (diagnosis). We included diagnosis variables in the adjusted model, as we considered that plasma Aβ42/Aβ40 might be differentially affected by disease status, and the diagnosis group was included in the model as a categorical variable (dummy variables: YC, OC, aMCI, and ADD). The AUC of multiple models was compared using the Delong method. Finally, we applied the prediction model to the SVCI cohort for the validation process. All analyses were conducted using the STATA version 15. Statistical significance was set at p < 0.05.

Data availability

Anonymized data for our analyses presented in this report are available upon request from the corresponding authors.


Characteristics of the participants

The detailed demographics and clinical characteristics of the 580 participants are presented in Table 1. The mean age of participants (n = 580) was 69.8 ± 11.0 years (range, 26–97 years). Females accounted for 62.4%, and the frequency of APOE4 carriers was 36.9%. All patients underwent Aβ PET, and Aβ positivity by the dcCL cutoff was 48.4%. Aβ positivity was 85.0% for ADD, 56.1% for aMCI, 11.4% for OC, 37.9% for SVCI, and 81.8% for CAA. No YC scans showed PET+ scans. The demographics of the study participants according to the diagnosis and PET positivity are shown in Supplementary Table 1.

Table 1 Demographics and clinical characteristics of the study participants

Comparison between plasma Aβ biomarkers and Aβ uptakes on PET

Figure 1 shows plasma Aβ42 (A), Aβ40 (B), and Aβ42/Aβ40 (C) according to Aβ PET positivity in the total group and in each diagnostic group. Plasma Aβ42 levels were significantly lower in the PET-positive groups than in the PET-negative groups, except for the ADD and CAA groups (total, aMCI p < 0.001; OC, p = 0.026; ADD, p = 0.057; SVCI, p = 0.002; CAA, p = 0.099) (Fig. 1A). Aβ40 was not significantly different between PET-positive and PET-negative groups (Fig. 1B). In all diagnostic groups except for CAA, Aβ PET-positive groups had significantly lower plasma Aβ42/Aβ40 levels than Aβ PET-negative groups (total, OC, aMCI, ADD, and SVCI, p < 0.001; CAA, p = 0.157) (Fig. 1C).

Fig. 1

A Plasma Aβ42, B Aβ40, and C Aβ42/Aβ40 according to Aβ positivity on PET in each diagnostic group. This box-and-whisker plot shows a box with a lower edge at the lower quartile (25%), upper edge at the upper quartile (75%), the middle of the box at the median, and the maximum and minimum as whiskers. Abbreviations: OC, old controls; aMCI, amnestic mild cognitive impairment; ADD, Alzheimer’s disease dementia; SVCI, subcortical vascular cognitive impairment; CAA, cerebral amyloid angiopathy; YC, young controls; PET, positron emission tomography

In the total group, baseline plasma Aβ42/Aβ40 was inversely correlated with continuous dcCL units with a Spearman’s rho of −0.508 (p < 0.001) (Fig. 2).

Fig. 2

Scatterplot of plasma Aβ42/Aβ40 and amyloid PET centiloid and their correlation. The cutoff value of PET centiloid and Aβ42/Aβ40 were 25.11 and 0.2576, respectively. Abbreviations: OC, old controls; aMCI, amnestic mild cognitive impairment; ADD, Alzheimer’s disease dementia; SVCI, subcortical vascular cognitive impairment; CAA, cerebral amyloid angiopathy; YC, young controls; PET, positron emission tomography

Concordance of plasma Aβ42/Aβ40 and Aβ positivity on PET

We performed ROC analysis in the YC, OC, aMCI, and ADD groups. The ROC analysis demonstrated that plasma Aβ42/Aβ40 alone was a good predictor of Aβ PET dcCL-based positivity, with an AUC of 0.814 (unadjusted model). The plasma Aβ42/Aβ40 cutoff with the maximum Youden index was 0.2576 and yielded a PPA of 75.8% and NPA of 76.7%. Using this cutoff, a good concordance rate between plasma Aβ42/Aβ40 and PET positivity was achieved (384/503 = 76.3%). The remaining 119 patients with discordant positivity included 60 plasma+/PET− and 59 plasma−/PET+ patients. When the cutoff was applied to all diagnostic groups, each group showed a high concordance rate (72.7 to 86.7%). In terms of discordant cases, OC showed more plasma+/PET− (n = 29) than plasma−/PET+ (n = 5) (p < 0.001), while ADD showed more plasma−/PET+ (n = 25) than plasma+/PET− (n = 6) (p < 0.001). However, the percentage of plasma+/PET− (n = 23) and plasma−/PET+ (n = 29) participants were not different in the aMCI group (p = 0.129) (Table 2, Fig. 3). When we investigated this discordance pattern with different PET positivity definitions using different CL cutoff values (24.6 and 20), the results remained similar as OC showed more plasma+/PET− and ADD showed more plasma−/PET+ cases (Supplementary Table 2).

Table 2 Performance of plasma Aβ42/Aβ40 to predict PET positivity and concordance with PET
Fig. 3

Scatterplot of plasma Aβ42/Aβ40 and Aβ PET centiloid in the A total, B OC, C aMCI, and D ADD groups. The dashed red lines indicate cutoffs for plasma Aβ42/Aβ40 (0.2576) based on the maximum Youden index and for Aβ PET centiloids (25.11) for amyloid PET positivity. The cutoff value of PET centiloid and Aβ42/Aβ40 were 25.11 and 0.2576, respectively. Abbreviations: total, total participants excluding YCs; OC, old controls; aMCI, amnestic mild cognitive impairment; ADD, Alzheimer’s disease dementia; SVCI, subcortical vascular cognitive impairment; CAA, cerebral amyloid angiopathy; YC, young controls; PET, positron emission tomography

We also performed ROC analyses for each diagnostic group. Particularly in the OC group, plasma Aβ42/Aβ40 alone predicted PET positivity. The AUC of 0.826 (PPA 94.1, NPA 62.6) plasma Aβ42/Aβ40 alone predicted PET positivity with good performance in all groups (AUCs, 0.812–0.826), which significantly increased in the age- and APOE4-adjusted models (AUCs 0.872 to 0.890) (Table 2).

Comparison of prediction models including different combinations of variables

We compared multiple models with different combinations of variables to evaluate whether adding plasma Aβ42/Aβ40 to the clinical variables increased predictive performance for Aβ positivity. We performed a 10-fold cross-validation in AD continuum to obtain the AUCs. As shown in Table 3, the AUC of the age and APOE4 model (model 3, Fig. 4) was 0.727, and it improved to 0.855 when Aβ42/Aβ40 was added (model 6). When we added the diagnosis group (cognitive stage) in addition to age, APOE4 status, and plasma Aβ42/Aβ40 in the model (model 7) to predict Aβ PET positivity, the AUC improved to 0.916. Except for model 2 vs. model 3 (p = 0.661) and model 5 vs. model 6 (p = 0.759), both individual models in Table 3 show statistically different AUC values (all p < 0.05) (Fig. 3).

Table 3 Models with different combinations of variables
Fig. 4

Receiver operating characteristic curves for Aβ42/Aβ40 and Aβ42/Aβ40 plus covariates for predicting amyloid positivity. Abbreviations: AUC, area under the receiver operating characteristic curve; Dx, diagnosis

When we applied these models to the SVCI cohort as a validation process, the AUC was shown to be as high as 0.823 in model 4 where Aβ42/Aβ40 was the only predictor (Table 3).


In the present study, we investigated the performance of plasma Aβ42/Aβ40 to predict PET positivity using HPLC-MS/MS in a large cohort of carefully phenotyped patients who were on the AD continuum or had SVCI. Our major findings were as follows. First, plasma Aβ42/Aβ40 corresponded well with Aβ PET results of patients on the AD continuum, such as those in the YC, OC, aMCI, and ADD groups. Second, the distribution of plasma+/PET− or plasma−/PET+ among discordant cases differed depending on the cognitive stage of the patients. Third, a 10-fold cross-validation in patients on the AD continuum showed that the predictive performance of plasma Aβ42/Aβ40, when combined with age, APOE genotype, and cognitive stage, increased to as much as 0.916. Finally, plasma Aβ42/Aβ40 had a good predictive performance even in the SVCI cohort. Taken together, our findings suggest that Aβ42/Aβ40 in human plasma, as measured by this novel HPLC-MS/MS method, may be useful to screen for Aβ PET positivity across diverse patients and reduce the expense for future clinical trials.

While earlier studies adopting ELISA methods have failed to prove the clinical utility of plasma biomarkers, the most recent study of fully automated plasma immunoassays showed a good performance of plasma Aβ42/Aβ40 with an AUC of 0.77 [10]. Especially, a few recent studies using IP-MS methods consistently showed good accuracy in predicting amyloid in the brain across heterogeneous cohorts [5, 8]. However, in our opinion, the HPLC-MS/MS method may provide more advantages compared to IP-MS. The outstanding feature of this method is that it does not involve any immunoprecipitation steps; thus, it is not affected by undesirable effects associated with antibodies such as cross-reactivity and batch-to-batch reproducibility. As it does not involve any additional enzymatic digestion step, intact Aβ40 and Aβ42 levels are quantifiable. Thus, in the present study, we chose to use this novel method to detect plasma Aβ. Our first major finding that plasma Aβ42/Aβ40 corresponded well with Aβ PET results of patients on the AD continuum is supported by the following observations: (1) the plasma Aβ42/Aβ40 levels were significantly different between the PET-positive and PET-negative groups; (2) the plasma Aβ42/Aβ40 levels were well-correlated with quantitative PET uptake measured by dcCL units; and (3) the plasma Aβ42/Aβ40 showed a good AUC in predicting Aβ PET results and a high concordance rate. This finding is consistent with previous studies that demonstrated a good performance of plasma biomarkers to predict amyloid PET status, with an AUC of 0.75 to 0.9 [5, 8, 10, 12].

Our second major finding was that among discordant cases, there were different distributions of plasma+/PET− or plasma−/PET+ depending on the cognitive stage. Specifically, most of the discordant cases in the OC group were plasma+/PET−, whereas those in the ADD group were plasma−/PET+. The ratio of plasma+/PET− and plasma−/PET+ was similar in the aMCI group. Previously, in terms of plasma, the distribution of discordant cases by cognitive stage had not been investigated extensively. However, previous CSF biomarker studies have shown that most of their discordant cases, especially those with normal cognition, were CSF+/PET−, supporting CSF Aβ as a more sensitive marker of early disease [42,43,44]. Interestingly, they showed that the number of discordant cases (CSF+/PET−) decreased along the dementia continuum [42, 45], which was congruent with our findings. Similar to CSF Aβ biomarkers, our results suggest that by reflecting soluble Aβ, plasma Aβ42/Aβ40 may be more sensitive in capturing earlier changes in brain β-amyloidosis in the OC group. In contrast, plasma−/PET+ cases were more commonly found in the ADD group, where Aβ plaques were already formed as a major pathology. Considering that Aβ PET changes are more likely to detect the fibrillary form of Aβ [46], it could be suggested that PET and plasma biomarker measures may not be directly interchangeable and instead reflect partially independent processes. However, as the unique discordance profile in ADD has not been observed in previous studies, to replicate our findings, further studies will be needed. In addition, 2 out of the 15 Aβ PET− YCs included in the present study as an absolute control group had a lower Aβ42/Aβ40 (0.240 and 0.244) value compared to the obtained cutoff value of 0.2576. Therefore, such discordant cases should also be followed up for further validation of plasma biomarker testing by HPLC-MS/MS.

Our third major finding was that adding plasma biomarkers to the clinical information had an incremental benefit in terms of predicting PET positivity. As we expected, in a 10-fold cross-validation study based on AD continuum, the predictive performance was improved to 0.916 when age, APOE4, and cognitive stage were combined with plasma biomarkers as predictors. Our finding has some clinical implications. Currently, more clinical trials tried to target high-risk but normal cognitive participants, who have Aβ deposition but do not have pronounced neurodegeneration. Under this circumstance, plasma Aβ42/Aβ40, particularly when combined with APOE status, could be utilized as the best screening tool because it is inexpensive and easily accessible, and this practical screening test for brain amyloidosis can subsequently reduce the number of amyloid PET scans required for diagnostic confirmation. Specifically, if we assume that the amyloid PET-positive rate is 20% in the elderly over 60 years, and the PPA (sensitivity) of plasma Aβ42/Aβ40 in the OC group is 94.1%, the number needed to screen would be 531, and the number proceeding to scan (plasma+) would be 259 [17]. Therefore, screening participants with plasma Aβ42/Aβ40 could reduce the number of confirmatory amyloid PET scans by 52%.

Our final major finding was that plasma Aβ42/Aβ40 had a good predictive performance even in the SVCI cohort. Previous studies have reported controversial findings between WMH, MRI marker of SVCI, and Aβ fluid biomarkers. While WMH was inversely associated with CSF Aβ isoforms (both Aβ42 and Aβ40) [47, 48], it was positively associated with plasma Aβ40 [3, 49]. Nevertheless, good predictive performance of plasma Aβ42/Aβ40 in the SVCI cohort suggests that plasma Aβ42/Aβ40 could be utilized as a screening tool even in the presence of extensive WMH. Previous studies have reported that CAA has decreased levels of fluid Aβ40 and/or Aβ42 because of vascular deposition of Aβ40 (predominantly), and to a lesser extent Aβ42 [50,51,52,53,54,55]. We expected that plasma Aβ40 and Aβ42 might also differentially decrease in CAA according to PET positivity; however, we could not find any difference in all three biomarkers between PET+ and PET− patients in the CAA group, although our results might have been underpowered because of the small number of participants. Therefore, a future study with a larger number of CAA participants is needed to investigate the unique changing direction of plasma Aβ40 and the predictive value of Aβ42/Aβ40 for Aβ PET positivity.


Although we included a large cohort of carefully phenotyped participants with a wide array of cognition and etiologies such as CAA or vascular dementia, our study also has several limitations. First, there was no pathologic confirmation to explain the discordant cases of plasma and PET results. In addition, all disease groups were clinically diagnosed; therefore, the presence of other pathologies such as argyrophilic grain disease or hippocampal sclerosis could not be excluded. Second, the number of SVCI and CAA participants was relatively small.


Nevertheless, we successfully demonstrated the potential clinical utility of plasma biomarkers in memory clinics, using a large number of memory clinic participants in Korea. Our results warrant further validation and development of this plasma Aβ assay, which together with other blood-based biomarkers, could speed up recruitment and reduce screening failure rate and associated costs, opening a new era of clinical trials. Our study also demonstrates the usefulness of a well-developed clinical cohort with research-ready biosamples for advancing AD biomarker studies.

Availability of data and materials

The data are publicly available and provided upon request.



Alzheimer’s disease


Alzheimer’s disease dementia


Amnestic mild cognitive impairment


Alzheimer’s disease-related cognitive impairment


Old controls


Subcortical vascular cognitive impairment


Cerebral amyloid angiopathy


Young controls


Area under the curve


White matter hyperintensity


Liquid chromatography-mass spectrometry


Negative percent agreement


Positive percent agreement


Positron emission tomography


  1. 1.

    Lee J, Jang H, Kang SH, Kim J, Kim JS, Kim JP, et al. Cerebrospinal fluid biomarkers for the diagnosis and classification of Alzheimer’s disease spectrum. J Korean Med Sci. 2020;35:e361.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  2. 2.

    Fandos N, Perez-Grijalba V, Pesini P, Olmos S, Bossa M, Villemagne VL, et al. Plasma amyloid beta 42/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst). 2017;8:179–87.

    PubMed  PubMed Central  Article  Google Scholar 

  3. 3.

    Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, et al. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology. 2006;66:23–9.

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Hernandez-Guillamon M, Delgado P, Penalba A, Rodriguez-Luna D, Molina CA, Rovira A, et al. Plasma beta-amyloid levels in cerebral amyloid angiopathy-associated hemorrhagic stroke. Neurodegener Dis. 2012;10:320–3.

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13:841–9.

    PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Pesini P, Perez-Grijalba V, Monleon I, Boada M, Tarraga L, Martinez-Lage P, et al. Reliable measurements of the beta-amyloid pool in blood could help in the early diagnosis of AD. Int J Alzheimers Dis. 2012;2012:604141.

    PubMed  PubMed Central  Google Scholar 

  7. 7.

    Risacher SL, Fandos N, Romero J, Sherriff I, Pesini P, Saykin AJ, et al. Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition. Alzheimers Dement (Amst). 2019;11:510–9.

    Article  Google Scholar 

  8. 8.

    Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93:e1647–e59.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Shanthi KB, Krishnan S, Rani P. A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer’s disease. SAGE Open Med. 2015;3:2050312115598250.

    PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease–related β-amyloid status. JAMA neurology. 2019;76:1060–9.

    PubMed  PubMed Central  Article  Google Scholar 

  11. 11.

    Verberk IM, Slot RE, Verfaillie SC, Heijst H, Prins ND, van Berckel BN, et al. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol. 2018;84:648–58.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  12. 12.

    Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, et al. High performance plasma amyloid-beta biomarkers for Alzheimer’s disease. Nature. 2018;554:249–54.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Roberts KF, Elbert DL, Kasten TP, Patterson BW, Sigurdson WC, Connors RE, et al. Amyloid-β efflux from the central nervous system into the plasma. Ann Neurol. 2014;76:837–44.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Pascale CL, Miller MC, Chiu C, Boylan M, Caralopoulos IN, Gonzalez L, et al. Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent. Fluids and Barriers of the CNS. 2011;8:1–11.

    Article  CAS  Google Scholar 

  15. 15.

    Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43:333–44.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Donahue JE, Johanson CE. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease. J Neuropathol Exp Neurol. 2008;67:261–70.

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Keshavan A, Pannee J, Karikari TK, Rodriguez JL, Ashton NJ, Nicholas JM, et al. Population-based blood screening for preclinical Alzheimer’s disease in a British birth cohort at age 70. Brain. 2021;144:434–49.

    PubMed  PubMed Central  Google Scholar 

  18. 18.

    Palmqvist S, Mattsson N, Hansson O. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain. 2016;139:1226–36.

    PubMed  PubMed Central  Article  Google Scholar 

  19. 19.

    Patterson BW, Elbert DL, Mawuenyega KG, Kasten T, Ovod V, Ma S, et al. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann Neurol. 2015;78:439–53.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  20. 20.

    Pietroboni AM, Scarioni M, Carandini T, Basilico P, Cadioli M, Giulietti G, et al. CSF β-amyloid and white matter damage: a new perspective on Alzheimer’s disease. Journal of Neurology, Neurosurgery &amp. Psychiatry. 2018;89:352–7.

    Google Scholar 

  21. 21.

    Kang SH, Park YH, Lee D, Kim JP, Chin J, Ahn Y, et al. The cortical neuroanatomy related to specific neuropsychological deficits in Alzheimer’s continuum. Dement Neurocogn Disord. 2019;18:77–95.

    PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Ahn HJ, Chin J, Park A, Lee BH, Suh MK, Seo SW, et al. Seoul Neuropsychological Screening Battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia patients. J Korean Med Sci. 2010;25:1071–6.

    PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    Petersen RC. Mild cognitive impairment: current research and clinical implications. Semin Neurol. 2007;27:22–31.

    PubMed  Article  Google Scholar 

  24. 24.

    McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.

    PubMed  PubMed Central  Article  Google Scholar 

  25. 25.

    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44.

    CAS  PubMed  Article  Google Scholar 

  26. 26.

    Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993;43:1683–9.

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Linn J, Halpin A, Demaerel P, Ruhland J, Giese AD, Dichgans M, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology. 2010;74:1346–50.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  28. 28.

    Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy: evolution of the Boston Criteria. Stroke. 2018;49:491–7.

    PubMed  PubMed Central  Article  Google Scholar 

  29. 29.

    Biffi A, Greenberg SM. Cerebral amyloid angiopathy: a systematic review. J Clin Neurol. 2011;7:1–9.

    PubMed  PubMed Central  Article  Google Scholar 

  30. 30.

    Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Annals of neurology. 2007;62:229–34.

    PubMed  Article  Google Scholar 

  31. 31.

    Kim HJ, Yang JJ, Kwon H, Kim C, Lee JM, Chun P, et al. Relative impact of amyloid-beta, lacunes, and downstream imaging markers on cognitive trajectories. Brain. 2016;139:2516–27.

    PubMed  Article  Google Scholar 

  32. 32.

    Jang H, Jang YK, Kim HJ, Werring DJ, Lee JS, Choe YS, et al. Clinical significance of amyloid beta positivity in patients with probable cerebral amyloid angiopathy markers. Eur J Nucl Med Mol Imaging. 2019;46:1287–98.

    CAS  PubMed  Article  Google Scholar 

  33. 33.

    Kim SE, Woo S, Kim SW, Chin J, Kim HJ, Lee BI, et al. A nomogram for predicting amyloid PET positivity in amnestic mild cognitive impairment. J Alzheimers Dis. 2018;66:681–91.

    CAS  PubMed  Article  Google Scholar 

  34. 34.

    Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273–89.

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Park JH, Seo SW, Kim C, Kim SH, Kim GH, Kim ST, et al. Effects of cerebrovascular disease and amyloid beta burden on cognition in subjects with subcortical vascular cognitive impairment. Neurobiol Aging. 2014;35:254–60.

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    Mormino EC, Brandel MG, Madison CM, Rabinovici GD, Marks S, Baker SL, et al. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage. 2012;59:1152–60.

    PubMed  Article  Google Scholar 

  37. 37.

    Kim H-R, Choe YS, Moon SH, Kim HJ, Jang H, L.Na D, et al. Finding the optimal cutoff value for amyloid β positivity using the iterative outlier method and concordance rate. Precis Future Med. 2021;0.

  38. 38.

    Cho SH, Choe YS, Kim YJ, Lee B, Kim HJ, Jang H, et al. Concordance in detecting amyloid positivity between (18)F-florbetaben and (18)F-flutemetamol amyloid PET using quantitative and qualitative assessments. Sci Rep. 2020;10:19576.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1–15 e1-4.

    PubMed  Article  Google Scholar 

  40. 40.

    Cho SH, Choe YS, Kim HJ, Jang H, Kim Y, Kim SE, et al. A new Centiloid method for (18)F-florbetaben and (18)F-flutemetamol PET without conversion to PiB. Eur J Nucl Med Mol Imaging. 2020;47:1938–48.

    CAS  PubMed  Article  Google Scholar 

  41. 41.

    Amadoru S, Doré V, McLean CA, Hinton F, Shepherd CE, Halliday GM, et al. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease. Alzheimers Res Ther. 2020;12:22.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  42. 42.

    Leuzy A, Chiotis K, Hasselbalch SG, Rinne JO, de Mendonca A, Otto M, et al. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-beta in a multicentre European memory clinic study. Brain. 2016;139:2540–53.

    PubMed  PubMed Central  Article  Google Scholar 

  43. 43.

    Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer’s disease. Brain. 2015;138:772–83.

    PubMed  Article  Google Scholar 

  44. 44.

    Reimand J, de Wilde A, Teunissen CE, Zwan M, Windhorst AD, Boellaard R, et al. PET and CSF amyloid-beta status are differently predicted by patient features: information from discordant cases. Alzheimers Res Ther. 2019;11:100.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Vos SJB, Gordon BA, Su Y, Visser PJ, Holtzman DM, Morris JC, et al. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiol Aging. 2016;44:1–8.

    PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    Ikonomovic MD, Buckley CJ, Heurling K, Sherwin P, Jones PA, Zanette M, et al. Post-mortem histopathology underlying beta-amyloid PET imaging following flutemetamol F 18 injection. Acta Neuropathol Commun. 2016;4:130.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  47. 47.

    Selnes P, Blennow K, Zetterberg H, Grambaite R, Rosengren L, Johnsen L, et al. Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. Cerebrospinal Fluid Res. 2010;7:10.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  48. 48.

    van Westen D, Lindqvist D, Blennow K, Minthon L, Nagga K, Stomrud E, et al. Cerebral white matter lesions - associations with Abeta isoforms and amyloid PET. Sci Rep. 2016;6:20709.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  49. 49.

    Hilal S, Akoudad S, van Duijn CM, Niessen WJ, Verbeek MM, Vanderstichele H, et al. Plasma amyloid-beta levels, cerebral small vessel disease, and cognition: the Rotterdam Study. J Alzheimers Dis. 2017;60:977–87.

    CAS  PubMed  Article  Google Scholar 

  50. 50.

    Charidimou A, Friedrich JO, Greenberg SM, Viswanathan A. Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: a meta-analysis. Neurology. 2018;90:e754–e62.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  51. 51.

    Renard D, Castelnovo G, Wacongne A, Le Floch A, Thouvenot E, Mas J, et al. Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria. J Neurol. 2012;259:2429–33.

    CAS  PubMed  Article  Google Scholar 

  52. 52.

    Verbeek MM, Kremer BP, Rikkert MO, Van Domburg PH, Skehan ME, Greenberg SM. Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. Ann Neurol. 2009;66:245–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  53. 53.

    Chatterjee P, Tegg M, Pedrini S, Fagan AM, Xiong C, Singh AK, et al. Plasma amyloid-beta levels in a pre-symptomatic Dutch-type hereditary cerebral amyloid angiopathy pedigree: a cross-sectional and longitudinal investigation. Int J Mol Sci. 2021;22.

  54. 54.

    Bornebroek M, De Jonghe C, Haan J, Kumar-Singh S, Younkin S, Roos R, et al. Hereditary cerebral hemorrhage with amyloidosis Dutch type (AbetaPP 693): decreased plasma amyloid-beta 42 concentration. Neurobiol Dis. 2003;14:619–23.

    CAS  PubMed  Article  Google Scholar 

  55. 55.

    van Etten ES, Verbeek MM, van der Grond J, Zielman R, van Rooden S, van Zwet EW, et al. β-Amyloid in CSF: biomarker for preclinical cerebral amyloid angiopathy. Neurology. 2017;88:169–76.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

Download references


We thank the members of the Mass Spectrometry Laboratory at Araclon Biotech for plasma analysis. This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF-2020R1A2C1009778), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) and Korea Dementia Research Center (KDRC), funded by the Ministry of Health & Welfare and Ministry of Science and ICT (HU20C0414), a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare (HI19C1132), and the Fourth Stage of Brain Korea 21 Project in the Division of Intelligent Precision Healthcare.


This study was funded by the DPUK through the Medical Research Council (MR/L023784/2).

Author information





HJ analyzed and interpreted the data and drafted the manuscript for intellectual contents. JSK contributed to the acquisition of data and data analysis. HJL contributed to the data analysis. CHK, DLN, HJK, JAA, LS, SC, and PP contributed to the acquisition of data. JG interpreted the data and revised the manuscript for intellectual content. SWS designed and conceptualized the study, interpreted the data, and revised the manuscript for intellectual content. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Sang Won Seo.

Ethics declarations

Ethics approval and consent to participate

The institutional review boards of all participating institutions approved the study procedures. Written informed consent was obtained from all participants or surrogates.

Consent for publication

Not applicable.

Competing interests

JAA, LS, SC, and PP are full-time employees of Araclon Biotech-Grifols, the manufacturer of the mass spectrometry test (ABtest-MS).

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Supplementary Figure 1.

Flowchart of sample selection. Supplementary Figure 2. Detailed method for amyloid PET imaging analysis and centiloid. Supplementary Table 1. Demographics of study participants according to the diagnosis and PET positivity. Supplementary Table 2. Demographics of study participants according to the diagnosis and PET positivity

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jang, H., Kim, J.S., Lee, H.J. et al. Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort. Alz Res Therapy 13, 179 (2021).

Download citation


  • Biomarker
  • Alzheimer’s disease
  • Amyloid
  • Plasma
  • Aβ42/Aβ40
  • Liquid chromatography-mass spectrometry